2021 年，EAU 指南实施了一项新颖的、基于专家意见的随访计划，针对透明细胞 (cc) 和非 cc 肾细胞癌 (non-ccRCC) 手术后以治愈为目的的三风险类别系统。我们的目的是验证新的随访方案，并根据风险组提供数据驱动的复发估计，以确认或实施肿瘤监测策略。我们从涉及 28 个法国转诊中心的前瞻性维护数据库中确定了 5,320 名患者。根据 ccRCC 或非 ccRCC 组织学，使用 Kaplan-Meier 方法评估每组（低风险、中风险或高风险）的复发风险，无论是局部区域还是远处复发。通过 LOWESS 平滑器以图形方式研究复发的非累积分布。2293 例 (58%)、926 例 (23%) 和 738 例 (19%) 患有低、中和高风险 ccRCC，并且分别有 683 名 (50%)、297 名 (22%) 和 383 名 (28%) 患有低风险、中风险和高风险非 ccRCC。幸存者的中位随访时间为 46 个月。总体而言，661 名患者出现复发。随着时间的推移，低风险cc-RCC、非ccRCC和中风险非ccRCC的非累积复发风险约为10%，三种复发函数之间无显着差异（P=0.9）。在 5 年（影像学检查应降低至每两年一次）的时间点上，非累积复发风险为： 中危 ccRCC 和非 ccRCC：分别为 15% 和 11%；对于高风险 ccRCC 和非 ccRCC：分别为 24% 和 8%。在高危非 ccRCC 患者中，3 个月时有 9 例复发。 3个月时影像学阴性的高危非ccRCC患者的复发功能与中危ccRCC患者的复发功能无显着性差异（P=0.3）。鉴于中危患者的复发风险相对较低对于非 ccRCC，可以对这些人采取与低风险类别类似的策略。同样，3 个月时影像学呈阴性的高危非 ccRCC 患者，可在 3 个月时间点后与中危 ccRCC 类似地进行随访。

In 2021, the EAU Guidelines implemented a novel, expert opinion-based follow-up scheme, with a three-risk-category system for clear cell (cc) and non-cc renal cell carcinoma (non-ccRCC) after surgery with curative intent. We aimed to validate the novel follow-up scheme and provide data-driven recurrence estimates according to risk groups, to confirm or implement the oncologic surveillance strategy.We identified 5,320 patients from a prospectively maintained database involving 28 French referral centers. The risk of recurrence, as either loco-regional or distant, was evaluated with the Kaplan-Meier method for each group (low- intermediate- or high-risk) according to ccRCC or non-ccRCC histology. The noncumulative distribution of recurrences was graphically investigated through the LOWESS smoother.Two thousand two hundred ninety-three (58%), 926 (23%), and 738 (19%) had low-, intermediate, and high-risk ccRCC, and 683 (50%), 297 (22%), and 383 (28%) had low-, intermediate, and high-risk non-ccRCC, respectively. Median follow-up for survivors was 46 months. Overall, 661 patients experienced recurrence. Over time, the noncumulative risk of recurrence was approximately 10% for low-risk cc-RCC, non-ccRCC, and intermediate-risk non-ccRCC, with non-significant difference among the three recurrence functions (P=0.9). At 5-year, time point after which imaging should be de-intensified to biennial, the noncumulative risks of recurrence were: for intermediate risk ccRCC and non-ccRCC: 15% and 11%, respectively; for high-risk ccRCC and non-ccRCC: 24% and 8%, respectively. Among high-risk non-ccRCC patients there were 9 recurrences at 3-month. There was no significant difference between the recurrence function of high-risk non-ccRCC patients with negative imaging at 3-month and the one of intermediate-risk ccRCC (P=0.3).Given the relatively low recurrence risk of patients with intermediate-risk non-ccRCC, those individuals could be followed up with a similar strategy to the low-risk category. Similarly, patients with high-risk non-ccRCC with negative imaging at 3-month, could be followed up similarly to intermediate-risk ccRCC after the 3-month time point.